Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI-Powered ECG could spot silent heart failure in minutes

NCT ID NCT07636759

Diagnosis Sponsor: Ajou University School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This study is testing a new artificial intelligence (AI) tool that analyzes electrocardiograms (ECGs) to find a condition called left ventricular systolic dysfunction (LVSD), a type of heart failure where the heart's main pumping chamber is weak. Researchers will enroll 15,000 adults who have had both an ECG and an echocardiogram (heart ultrasound) within 30 days. The goal is to see how well the AI can detect LVSD compared to the standard ultrasound test, potentially allowing for faster and easier diagnosis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this AI could help doctors spot heart failure earlier using a simple, quick ECG, potentially saving lives.
What could go wrong
This is an observational study, not a treatment trial. The AI may not be accurate enough in real-world settings, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients aged 19 years or older undergoing routine clinical care at Ajou University Hospital who have both transthoracic echocardiography and 12-lead electrocardiography (ECG) performed within 30 days. Participants may be recruited from outpatient clinics, inpatient wards, or the emergency department.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged ≥19 years. * Patients who underwent both transthoracic echocardiography and 12-lead electrocardiography (ECG) at Ajou University Hospital in the outpatient, inpatient, or emergency department setting. * ECG and echocardiography performed within 30 days of each other. Exclusion Criteria: * Interval between ECG and echocardiography greater than 30 days. * Missing or corrupted original ECG waveform data (XML or HL7 format). * Presence of an implanted cardiac device, including a permanent pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization therapy (CRT) device. * Missing age, sex, or left ventricular ejection fraction (LVEF) data.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HF - heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HF - heart failure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ajou University School of Medicine

    RECRUITING

    Suwon, Gyeonggi-do, 16499, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.